ARCA Biopharma

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, ARCA Biopharma sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 8 completed top decile by trial count

ARCA Biopharma: 10 sponsored US clinical trials, none currently recruiting.

ARCA Biopharma sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arterial Occlusive Diseases, with 2 trials.

Top-decile sponsor footprint

ARCA Biopharma ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 2

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

NCT04655586
COMPLETED Phase 2

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
TERMINATED Phase 2

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

NCT00499902
TERMINATED Phase 3

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
COMPLETED Phase 3

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

NCT00322270
COMPLETED Phase 3

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters

NCT00346424
COMPLETED Phase 2

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
COMPLETED Phase 3

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
COMPLETED Phase 2

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
COMPLETED Phase 2

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

NCT00073515

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 4

Therapeutic Areas

Arterial Occlusive Diseases 2
Thrombosis 2
Catheter Occlusion 1
Venous Thrombosis 1
Peripheral Vascular Diseases 1

How the ARCA Biopharma archive is shaped

10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).

Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).

Top condition: Arterial Occlusive Diseases (2 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

ARCA Biopharma: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

ARCA Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share ARCA BiopharmaAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
ARCA Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ARCA Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ARCA Biopharma page

10 registered trials is a research-attention snapshot, not an endorsement of ARCA Biopharma or any single study.

  • None of ARCA Biopharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Arterial Occlusive Diseases is the condition ARCA Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arterial Occlusive Diseases trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

ARCA Biopharma pipeline card: 10 registered trials from official public datasets.Report a data error.